KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment

Fluoropyrimidine-based chemotherapy plus antibody therapy is currently the standard first-line treatment for metastatic colorectal cancer (mCRC). In this study, we investigated the hypothesis that mutations in several of the targeted oncogenes are correlated with treatment outcomes in mCRC patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: SOEDA, HIROSHI, SHIMODAIRA, HIDEKI, WATANABE, MIKA, SUZUKI, TAKAO, GAMO, MAKIO, TAKAHASHI, MASANOBU, KOMINE, KEIGO, KATO, SHUNSUKE, ISHIOKA, CHIKASHI
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2014
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3999142/
https://ncbi.nlm.nih.gov/pubmed/24772300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2014.254
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados